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Death is a daunting thing. And
to make it worse, certifying
someone dead can be terrifying,
as Jean Adams found out (see
p 86). Sabina Dosani gives a
step by step guide to one of
those skills you just never seem
to be taught at medical school
A death certificate, or more correctly, a cer-
tificate for registration of death, is the docu-
ment used to register death. Without one,
funerals cannot go ahead. Filling out your
first death certificate can be a daunting task.
It is important to learn how to do it cor-
rectly as errors may result in a delayed
funeral and cause further distress to
Dead cert: 
a guide to death certificates
(Right)
How a death certificate looks, front (above)
and back (below).
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bereaved relatives.
A doctor may complete a certificate for
registration of a death only if he or she has
been in attendance on the deceased during
the last illness and has seen the deceased
within 14 days of death or after death. If no
doctor meets these criteria the coroner is
informed in England and Wales. In Scotland,
it is the procurator fiscal who has a duty to
investigate all sudden, suspicious, accidental,
unexplained and unexpected deaths, and
any death occurring in circumstances that
would give rise to serious public concern.
There are four potential outcomes:
 An uncertified death
 Death certified by a doctor
 Death certified after a postmortem
examination without an inquest
 Death certified after an inquest
Uncertified death is rare
An uncertified death is rare. For instance, a
dying patient attended before death by the
GP who discussed this with his or her part-
ners and then emigrated to Australia. No
doctor fulfilling the criteria to complete the
certificate would be available. If such a
death is reported to the coroner or procu-
rator fiscal, he or she may allow an uncerti-
fied death, without requesting a post-
mortem examination or inquest. After the
Harold Shipman case this is very unlikely.
It is worth knowing where the death cer-
tificates are kept. Usually this is in a
bereavement office, but smaller hospitals
may have other arrangements. They are in
Box 1: Cases which have to
reported to the coroner
 Violent deaths
 Deaths when a doctor has not
attended in the previous 14 days
 Cause of death is unknown or uncer-
tain
 Accidental death
 Doubtful stillbirth
 Deaths related to surgery or anaes-
thetic
 Deaths within 24 hours of admission
to hospital
For some deaths, you can issue the certifi-
cate for registration but can alert the
coroner or other authorities (such as a
pension agency) by ticking a box (box
A) on the reverse that further action
may be required. Examples of this are
given in box 2.
Box 2: Cases where further
action may be required
 Death from an industrial disease
 Death of a person who was in receipt
of an industrial pension
 Death by suicide
 Death by poisoning or drugs (includ-
ing alcohol)
 Death as a result of illegal abortion
 Death from want, neglect, or exposure
Box 3: Information on the certificate for registration
 Name of deceased
 Age
 Date of death
 Place of death
 Date last seen by the doctor issuing the certificate for registration
 This doctor can circle one or more of the following statements:
(a) This certificate takes account of information obtained from a postmortem
examination
(b) Information from the postmortem examination may be available later
(c) A postmortem examination not being held
(d) I have reported this death to the coroner for further action
 There is also an option for one of the following statements:
(a) Seen after death by me
(b) Seen after death by a another medical practitioner but not by me
(c) Not seen after death by a medical practitioner
 Cause of death which is in two parts:
(1a) Primary cause of death ……(and duration, but this is not obligatory)
(1b) Due to ……(and duration, but this is not obligatory)
(1c) Due to ……(and duration, but this is not obligatory)
(2) Significant conditions not related to primary cause of death (can be more than
one)
 You can tick a box if the death is related to employment. It is important to discuss the
implications of this with your seniors as it may influence a widow’s pension.
 Signature of doctor
 Date of issue
 Qualifications of doctor
 The name of the consultant responsible for the deceased if they died in hospital
Example 1
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a format similar to a large cheque book.
There are three sections of paper, separated
by perforations. The largest piece is the cer-
tificate for the registration of death; to the left is
a counterfoil for hospital records that
remains attached to the book; and on the
far right is a notice to informants, summaris-
ing the information.
Ensure that you are authorised to
complete the death certificate. As a house
officer, ensure that you have looked after
the patient within 14 days before death
and you know the cause. If you are
unsure about the cause of death read
through the patient’s notes and discuss
them with your seniors. If the cause of
death remains unclear the death will
probably need to be referred to the coro-
ner. Some deaths must be automatically
referred to the coroner. Informing the
coroner is compulsory in certain circum-
stances (see box 1).
Relatives appreciate it if you translate
medical jargon, such as myocardial infarction
and cerebrovascular accident into lay terms:
“heart attack” and “stroke.” It is good practice
to put these lay terms in brackets after the
medical terms on the counterfoil section.
Example 1
Frieda Smith, a 78 year old retired school
teacher, is registered blind secondary to
her diabetic retinopathy and so does not
see her dropped novopen on the floor. She
falls over it, hurting herself and is unable to
move. Sadly, she remains on the floor for
three days before being discovered by a
neighbour. You are the house officer 
on call at her local district general hospital.
She has fractured her neck of femur and
you are instructed to prepare her for 
theatre. However, she becomes suddenly
dyspnoeic and you see that the electrocar-
diograph (ECG) shows sinus tachycardia.
Her arterial blood gases suggest respira-
tory failure. A ventilation perfusion scan
shows ventilation and perfusion mismatch.
Mrs Smith has a cardiorespiratory arrest.
You start cardiopulmonary resuscitation
and put out a crash call. After 20 minutes’
resuscitation, she remains unresponsive
and the crash team decides to stop.
Frieda Smith’s death certificate
(1a) Pulmonary embolus (hours)
You can justify this because of the ECG,
blood gas results, and scan result. Note that
uninvestigated shortness of breath three
hours before death alone would be no good.
(1b) Fat embolus (days)
From her fractured neck of femur
(2) Insulin dependent diabetes mellitus
(20 years)
Example 2
Mabel Green is 68 and was admitted after
presenting with pain in her arms, legs, and
ribs. Her bones are tender and skeletal x ray
examinations show “punched out” oste-
olytic lesions. Bone marrow aspirate con-
tains abundant plasma cells and your team
diagnoses myeloma. Mrs Green is treated
with chemotherapy but develops renal fail-
ure. She and her family ask that she should
not be resuscitated in the event of a cardiac
arrest. She dies suddenly, during one of
your nights on call. You suspect she has
perished from a hyperkalaemic cardiac
arrest.
Mrs Green’s death certificate
(1a) Tumour lysis syndrome (two weeks)
(1b) Myeloma (five months)
Remember, you cannot give renal failure
or cardiac arrest as a cause of death.
Example 2
Example 3 (see p 57)
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Example 3
Arthur Pink is a 72 year old retired docker.
Six months ago he was diagnosed with
multi-infarct dementia and his wife Grace
has been struggling to control his diabetes
as he has become reluctant to cooperate
with blood glucose monitoring. He has
been hypertensive for 20 years but recently
has been forgetting to take his antihyper-
tensive medication. One morning he falls
to the floor and Grace notices that he can-
not move his left side. He is admitted to
hospital where your team is on call. You
diagnose a cerebrovascular accident.
Despite treatment and secondary preven-
tive measures, he dies four days later.
Mr Pink’s death certificate.
In brackets is the sort of lay terminology
that you might like to include for relatives.
(Ia) Cerebrovascular accident (stroke)
Four days
(Ib) Atherosclerosis (hardening of the
arteries) Five years
(Ic) Hypertension (high blood pressure)
20 years
(2) Diabetes mellitus (10 years)
Multi-infarct dementia (six months)
Sabina Dosani senior house officer in psychiatry, St
Thomas’s Hospital, London 
s.dosani@medix-uk.com
All the scenarios in this article are fictitious and
not based on any particular patient.
Diet is an important factor in forming
healthy bones. The mineral calcium is
obtained from the diet and deposited in
bones and teeth. Vitamin D is required for
this process.
A healthy diet providing adequate cal-
cium at all stages of life, coupled with an
active lifestyle, will help to ensure strong
bones. This is particularly important during
childhood, adolescence, and early adulthood
when bones are developing. Peak bone 
mass is reached at the age of about 30 to 35.
It is the stage at which the skeleton is
strongest. After this age bone mass
decreases. Optimising peak bone mass at
skeletal maturity provides important protec-
tion against osteoporosis in later life.
Around 90-95% of peak bone mass is
attained by the end of the second decade.
Adolescence is a particularly critical period,
with approximately 40% of peak bone mass
in girls being laid down during this time.
This process is under strong genetic control
but other determinants include physical
activity, especially weight bearing exercise,
such as brisk walking, running, and climbing
stairs, and nutritional factors, such as dietary
calcium and blood levels of vitamin D.
Osteoporosis
Osteoporosis is an increasing problem in
the United Kingdom. It causes considerable
pain and disability and costs the NHS in
excess of £940m to treat each year.1 It is a
disease characterised by loss of bone mass
and a deterioration in structural strength, in
which the bones become fragile and sus-
ceptible to fracture, particularly at the hip,
wrist, and spine. Osteoporosis most fre-
quently affects older women who have
gone through the menopause but it can
affect men and younger women. One in
three women and one in 12 men suffer
from osteoporosis in the United Kingdom.
Providing the hormones—in the form of
hormone replacement therapy (HRT) that
the body lacks, as a result of the
menopause, can help prevent bone loss in
women.
Recommended intake of calcium
There is currently no international consen-
sus as to exact recommendations for cal-
cium intake. This is partly because some
focus on meeting requirements, others for
optimising bone density. Recommended
intakes for young adults vary. Calcium
requirements within the UK were re-
appraised in 1998 and the recommended
intake of 700 mg of calcium a day for adults
aged 19 to 50 was reaffirmed.1 In contrast a
United States report recommended
1000 mg a day.2
The National Diet and Nutrition Survey
(NDNS) of people aged 4 to 18 showed that
about 10% of older boys (11 to 18) and 20%
of older girls had calcium intakes below the
lower reference nutrient intake—that is,
intakes that are likely to be inadequate.3 In
the NDNS survey of British adults aged 16 to
64 the average intake of those aged 16 to 24
was significantly lower than those aged 35 to
64 years.4
Research findings
Intervention studies indicate that bone min-
eral density can be increased in the short
term with increased calcium intake. In eld-
erly people fracture rate is lower in those
with a higher calcium and vitamin D intake.
Several randomised controlled trials have
now investigated the link between calcium
intake and bone mineral density. Bonjour
and colleagues found a greater increase in
bone mineral density among 8 year old girls
taking an extra 850 mg of calcium compared
with those on their normal diet.5 This study
also showed that the response to calcium
supplementation depended on habitual cal-
cium intake. Girls who had previously had
the lowest calcium intake (<880 mg a day)
benefited most from supplementation.
Research suggests that encouraging an
increase in dairy food consumption could
produce significant gains in bone density in
children and adolescents. Cadogan and col-
leagues supplemented 80, 12 year old girls
with an average of 330 ml of milk a day for
18 months.6 Bone mineral density increased
to a greater extent in the supplemented
group compared with those who had no extra
milk. Some of the benefit may be due to other
nutrients besides calcium as milk contains
several other nutrients which may be essential
for bone growth, including protein, phospho-
rus, magnesium, zinc, and B vitamins.
A recent review concluded that an
increase in calcium intake during growth
increases bone mineral by approximately 
1-5%, depending on the skeletal site meas-
ured.7
Despite good evidence for a short term
benefit of calcium supplementation, it is not
clear if this persists once the supplement 
is withdrawn. Short term increases in 
calcium or dairy food intake in children or
adolescents may not be sufficient to sustain
an increase in bone mass over several
decades. Previous studies have found differ-
ences in bone mineral density to disappear
18 months to two years after the withdrawal
of the calcium supplements.89
The ongoing Cambridge Bone Study is
seeking to determine whether advising young
people aged 16 to 18 to increase calcium
intake (to 1000 mg a day), as well as increas-
Diet and bone health
In the sixth article in our series on nutrition, Sarah Schenker explains the importance of calcium and
vitamin D
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ing exercise levels, provides an effective
means of optimising bone mineralisation.
This study will also measure the effects 12 to
18 months after the end of the intervention.
Dietary sources of calcium
As well as milk and dairy products, such as
yoghurt and cheese, which are the major
calcium providers in the diet, calcium is also
obtained from bread (a statutory require-
ment exists in the United Kingdom that
white flour should be fortified with calcium,
iron, vitamin B1, and vitamin B2), pulses,
green vegetables, dried fruits, such as apri-
cots, nuts, and seeds, and the soft bones
found in canned fish.
Vitamin D
Vitamin D is important for the absorption
of calcium. Bone loss may be significantly
reduced in postmenopausal women whose
diets are supplemented with 700 IU vitamin
D daily. Other nutrients may also be impor-
tant, such as magnesium, potassium, fibre,
vitamin C, and zinc to be associated with a
significantly higher lumbar spine bone min-
eral density.10
Vitamin D plays a vital role in calcium
homeostasis and bone metabolism. Vitamin
D insufficiency causes a change in serum
free calcium which in turn stimulates
parathyroid hormone secretion and
mobilises calcium from bone. The clinical
deficiency diseases rickets, which affects
infants and children when bones are grow-
ing, and osteomalacia, which affects adults
whose bone growth is completed, are rare in
the United Kingdom, although cases are still
sporadically reported.
But poor vitamin D status has substantial
public health implications since it may be an
adverse factor in developing osteoporosis.
An adequate vitamin D status throughout
childhood is likely to influence achieving
peak bone mass.
Older people
Supplementation with calcium and vitamin D
in older men and women reduces bone loss at
several sites and decreases rates of non-verte-
bral fractures.11 Ensuring an optimal intake of
both calcium and vitamin D is, therefore, an
important strategy to maintain existing bone
mass and reduce fracture in older people.
The NDNS of people aged 65 years and
over found that approximately 98% had vita-
min D intakes below the level recommended
(the recommended nutrient intake for this
age group is 10 µg a day).12 A large proportion
also had low vitamin D status (low plasma lev-
els), particularly those living in institutions as
they had little exposure to sunlight.
The NDNS of people aged 4 to18 years
found a low vitamin D state in a significant
proportion of those surveyed.4 In both boys
and girls, this problem increased with age.
This may be linked with a reduction in the
amount of time spent playing outside (thus
exposure to sunlight).
Sources of vitamin D
Diet: The best dietary sources of vitamin D
are oily fish—for example, herring, mack-
erel, salmon, trout—fortified margarines
and spreads, meat and meat products, and
eggs. The vitamin can also be synthesised
through the action of sunlight on the skin,
and for most people this provides the major
source. Vitamin D levels fall in winter as
skin synthesis declines.
Sunlight: Older people are vulnerable to
vitamin D insufficiency because the skin
becomes less efficient at synthesising vitamin
D with age as the epidermis thins. The
amount of pigmentation in the skin also
influences its capacity to synthesise vitamin
D and those with darker skin require longer
exposure to ultraviolet light. Certain ethnic
groups in the United Kingdom are, there-
fore, vulnerable to vitamin D deficiency and
advised to take a supplement. There are also
several cultural characteristics among these
groups that adversely affects vitamin D sta-
tus, including wearing concealing clothes
and excluding meat and fish from the diet.
Encouraging children to be more physi-
cally active should ensure sufficient sunshine
exposure and achievement of optimal peak
bone mass.
Increasing vitamin D intake from the diet
or through supplementation is likely to be of
benefit for vulnerable groups who rely on
dietary sources as a means of achieving an
adequate state, particularly during the winter
months. In the United Kingdom these vul-
nerable groups include children from Asian
communities, whose skin pigmentation
reduces absorption of sunlight, those who
wear clothes which fully conceal them, older
people who are housebound or seldom go
out, and those living in institutions.
The British Food Foundation is an independent
charity, which raises funds from the food indus-
try, the government, the EU Commission, and
other sources.
Sarah Schenker British Nutrition Foundation, London 
s.schenker@nutrition.org.uk
1 Department of Health. Nutrition and bone health. Lon-
don: DoH, 1998.
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Panel. Optimal calcium intake. JAMA 1994;272:1924-8.
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HMSO, 2000.
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and nutritional survey of British adults. London:
HMSO, 1990.
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calcium supplementation. J Bone Miner Res
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9 Lee WTK, Leung SSF, Leung DMY, Cheng JCY. A
follow-up study on the effects of calcium-supplement
withdrawal and puberty on bone acquisition of chil-
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Jason and the argonauts discover that calcium and vitamin D help grow strong skeletons
STUDENTBMJ VOLUME 10 March 2002 studentbmj.com 59
End of life care is an art—it is a challenging
and essential area of medical practice.
There is no specialty without such responsi-
bility at least from time to time.
Components of such care includes identi-
fying that death is approaching; discussion
with the patient and family and carers or
both; the identification and management of
distressing symptoms; support for family and
carers and bereavement support; and, if we
are to do it well, looking after ourselves.
When are the last days?
In this article we refer to the last few days of
life, when the final decline on the back-
ground of a progressive illness has begun—
this is not always easy to identify and others’
perspectives must be added to it. Nursing
staff have longer periods of direct patient
contact and their impression should be
noted. Families (in which we include all
“significant others” and not only relatives)
and, when lucid, patients may perceive
signs of imminent death. They may have no
special knowledge of dying but have a
unique insight and their impressions often
add sensitivity to the identification of end of
life events. It is less difficult to predict end
of life in patients with incurable cancer than
in other patients. Some of the most impor-
tant indicators that life is coming to end
are:
 Progressive and profound weight loss
 Profound weakness
 Impaired cognition
 Reduced oral intake and difficulty in 
taking oral medication
Sometimes there is a tendency for people
to withdraw from a dying person, and pro-
fessionals are not immune from this. This
may be a fear of death or lack of confidence
that they will know what to say or do. Very
often, little needs to be said or done, but the
act of not withdrawing, of continuing to go
into the side room rather than guiding the
ward round past the dying, is valuable in its
own right.
Broadening decision making and
teamwork
One of the hallmarks of palliative care—and
this should be applied equally to end of life
care whatever the arena—is the involvement
in decisions of patients and, where appro-
priate, families. Examples are decisions
such as where the patient may wish to die
and the use of possible life prolonging
treatment and possibly futile interventions—
for example, antibiotics. Most patients want
doctors to discuss such issues. They may
not be able to ask about it openly because
of fear and anxiety or may think that they
would be wasting the doctor’s time. It is not
unusual for families to withhold such infor-
mation from the patients, as they fear its
adverse impact. It would be useful again to
allay their anxieties and explore reasons for
such a request. It should be made clear that
if a patient wants to know, it is a doctor’s
duty to give the patient honest information.
Effective care at the end of life is a multi-
disciplinary and multiprofessional task.
Doctors and nurses are commonly the
main professionals, but in some cases there
is a need for others’ involvement—for
example, chaplains, social worker, physio-
therapist, and possibly the specialist pallia-
Only one chance to get it right: end of life care
Mari Lloyd-Williams, Sanjay Shah, and Idris Baker explain the fundamentals of palliative care and
supporting dying patients
Principles for managing symptoms
Symptoms Treatment Comments
Pain Paracetamol
Non-steroidal anti-inflammatory drugs
Adjuvant analgesics, such as anticonvulsants
Opioids
Steroids
Dyspnoea Opioids Look for easily and non-invasively reversible 
Benzodiazepines causes, such as bronchospasm
Oxygen
Complementary treatments
Nausea/vomiting Metoclopramide Look for reversible causes, such as 
Cyclizine constipation, and in selected group 
Haloperidol hypercalcaemia or urine tract infections. Stop all 
Methotrimeprazine non-essential drugs
Steroids
Confusion Haloperidol Don’t forget: urine retention and constipation 
can cause confusion in terminally ill
Review drug chart
Agitation/restlessness Midazolam Again, remember urine retention and 
Haloperidol constipation
Methotrimeprazine
Noisy breathing Hyoscine butylbromide It is frequently more distressing to carers,
Glycopyrronium relatives, and fellow patients
Suction
Urinary incontinence/retention Catheterisation 
Dry/sore mouth Good oral hygiene Rule out oral thrush 
Oral balance gel Avoid temptation to use IV
Frequent moistening of mouth fluids to relieve this symptom
Frequent sips of water
Ice cubes
Artificial saliva
Vitamin C
Extreme fatigue Steroids Very difficult to treat
In a highly selected group of patients, blood 
transfusion may be appropriate
Constipation Bisacodyl suppositories
Stool softeners
Terminal restlessness Midazolam 
Psychological and Reassurance Role of chaplain and priest can be very
emotional issues: fear, Discussion important
anxiety, loss of control, Empathy
helplessness, hopelessness, The art of “being” rather than “doing”
feelings of guilt, grieving for or “saying”
loss of family Sedation
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tive care team. In addition many areas now
have community nursing care—for exam-
ple, “hospital at home” or “hospice at
home” which undertake care of patients
who are dying in the community. Where
many professionals are involved good
communication is essential both between
colleagues and with the patient and their
family.
Ongoing evaluation and symptom
control
Patients’ needs at the end of life can be
complex. A marked proportion of patients
(though not all) will develop new symptoms
or worsening of existing symptoms. Patients
may not mention these spontaneously due
to exhaustion or the assumption that noth-
ing can be done to help—for example, con-
stipation. Full examination may cause
discomfort so a detailed appropriate exami-
nation should be carried out. Investigations
have little if any role to play in end of life
care, and procedures such as repeated
blood tests are unnecessary and distressing
to patients.
Common symptoms include
 Pain
 Dyspnoea
 Nausea or vomiting
 Confusion
 Agitation or restlessness
 Noisy breathing
 Urinary incontinence or retention
 Dry or sore mouth
 Extreme fatigue
There are non-pharmacological and
pharmacological treatments for virtually any
problem. Pain caused by an unstable fracture
in a dying patient unfit for surgery may be
treated effectively by gentle immobilisation
and analgesia.
Although drugs are a large part of the
management of many symptoms at the end
of life, it is as important to stop some drugs
as it is to start others. Oral medications often
become difficult to take and most long term
drugs may be stopped—for example, a dying
patient does not need drugs to lower their
blood pressure, slow their heart rate, or
lower their cholesterol levels. Often the best
approach is to stop everything except what is
clearly still needed.
General principles for the management
of common and some other symptoms is
outlined in the table.
Many patients are unable to swallow for a
short period before death, and medication
previously given orally must be given by a
parenteral route—for example, in a syringe
driver. Regular injections or suppositories
are less well tolerated but subcutaneous
injections can be used when needed as a
back up. Syringe drivers for continuous 
infusion should be universally available and
most of the drugs needed at the end of life
can be given by this route. Drugs that can be
administered using syringe drivers include
diamorphine, haloperidol, cyclizine, metoclo-
pramide, methotrimeprazine, midazolam,
steroids, and hyoscine.
It is important to remember that for good
symptom control in the last few days we
need to assess, explain, reassure, treat, and
review.
Support for family and carers
Family and carers should be actively
involved in caring for their loved ones if
they so wish. Acknowledge their physical—
for example, exhaustion—psychological,
and emotional needs and help them to
cope by listening and supporting and if
appropriate giving them a chance to say
“goodbye.” Do not ignore children and
elderly members of the family—they may
seem fragile, but usually cope well if kept
well informed and supported appropri-
ately.
After the death
Always show sympathy to relatives—they will
remember this time vividly and many com-
plaints to hospitals and trusts are made as a
result of harsh or insensitive words at the time
of a death. Listen to them patiently and be
prepared to go through what has happened
again. Explain about the administrative proce-
dure—for example, that a death certificate will
be issued and that they will be required to reg-
ister the death before making any funeral
arrangements. Relatives may feel utterly sad,
numb, or elated and thankful that their rela-
tive’s suffering is over. Remember to acknowl-
edge that all such feelings are normal and that
grief is a rollercoaster of emotions. Encourage
the family to make and maintain contact with
the primary care team who will possibly have
known the family well for several years and be
able to offer ongoing support.
Lastly, remember that care of the dying is
not a passive, but an active and potentially
exhausting yet a rewarding act. Some deaths
will affect us more than others; shedding
tears and feeling sad is not a failure for a doc-
tor, but reminds us that we too are human.
Mari Lloyd-Williams palliative care consultant and lecturer,
m.lloydwilliams@tesco.net
Sanjay Shah specialist registrar in palliative care, 
Idris Baker specialist registrar, LOROS Hospice, Leicester
Further reading
Fallon M, O’Neill B. ABC of palliative care. Lon-
don: BMJ Publishing Group, 1998.
Twycross R. Symptom management in advanced can-
cer. 2nd ed. Abingdon: Radcliffe Medical Press, 1997.
National Council of Hospice and Specialist Pal-
liative Care. Changing gear: guidelines for manag-
ing the last days of life in adults. NCHSPC,1997.
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If placebos are inactive, what is it that pro-
duces the remarkable changes? Do not ask
what the placebo can do but, “What can the
thing that responds to the placebo do?” You
will end up thinking about self healing and
self destructive processes.
Just as you can work backwards from a
successful recovery to study healing reac-
tions,1 you can consider what placebo reac-
tions say about healing responses and better
care. If placebo can provoke a change indi-
rectly perhaps we can learn to do so directly,
because we are the only possible pathway for
placebo action. The implications of this
pathway, between our consciousness and
our biology, can be missing in academic
debate about placebo,2 3 4 but the discovery
that people responding to placebo show def-
inite brain scan changes can bring it back
into focus.5
What can the placebo effect do?
Distress can be modified—as, for example,
physical pain: in one study saline was as
effective as morphine in 40% of people
after surgery.6 The same goes for emotional
pain: about 70% of patients respond to
placebo for depression.7 So is the placebo
effect all just in the mind? Does it only
modify experience, not “objective” reality?
When we blush when embarrassed is it
“real”? It is as real as the quantitative
electroencephalograph brain scans showing
reduced prefrontal cortex activity in people
responding to placebo antidepressants.5
How many respond?
It is often misquoted that one in three
people are placebo responders. This is
based on Beecher’s original work analysing
1082 cases where “35.2% responded.” The
range, however, was 18-52%.8. Reported
rates vary from less than 10% to more than
70% according to circumstances and con-
text. Everyone has self healing potential.
Who responds?
There is probably no simple predictive
measure of whether someone will or will
not respond. People who respond to
placebo have normal personalities, and
those who do not have more rigid personal-
ities, are suspicious, and sometimes do not
respond to “ordinary medicine.”9 Maybe it
is only the gullible who respond: medical
students respond more than most. In a
study on the effects of psychotropics, of 300
medical students 50% had psychological
changes and 60% had physical effects. They
identified the pink pills as stimulants and
the blue pills as sedatives. They were all
placebos.10
What form?
The physical form of the intervention has
an impact. Larger placebo capsules are
viewed as stronger, and two are stronger
than one. Injections produce larger effects
than pills. Red capsules and yellow capsules
tend to act as stimulants or antidepressants,
blue capsules as sedatives, and white cap-
sules as analgesics or narcotics.11 12 13
Symbolism has impact, and none more so
than the ritual of surgery.13 Surgeons made
skin incisions in patients expecting to have
their internal mammary artery tied to help
blood flow to their heart, to help with their
angina. A random selection of patients, how-
ever, never had the operation and the inci-
sion was sewn back up. All 18 non-treated
patients had less angina six weeks afterwards,
some had improved exercise electrocardio-
graphs, and the effect lasted for years in
some.14
In which culture?
The advertisements, the packaging, and the
hypnotic names carry messages—for exam-
ple, “Welldorm” for insomnia and “Mar-
velon” as a marvellous contraceptive.15 The
brand name on that free plastic pen the
drug representative gives to us has an
effect. In one study, branded tablets were
significantly more effective than unbranded
tablets for the treatment of headaches.16 A
powerful message in one culture may be
meaningless in another.
Expecting what?
You tend to get what you expect. From
aspirin placebo you get aspirin-like effects;
from morphine you get morphine-like
effects and side effects. This system has puz-
zling specificity, and placebos interact with
drug action synergistically or disruptively.
Bronchoconstriction due to atropine and
other anticholinergics can be reversed by
suggestion (with saline inhalation) and
bronchoconstriction of suggestion can be
blocked by ipratropium.17 Your previous
experience and learning all have an effect
like Pavlov’s dogs salivating to the sound of
the feeding bell. Rats given repeated scopo-
lamine injections show the same depressed
behaviour when given later placebo injec-
tions.18 If a prescription helped (say in
reducing your anxiety), you might repeat
what you “learned” to a later placebo ver-
sion of the same treatment. So it is better to
“anchor” the patient on their own self cop-
ing than on you or your treatments.
Drugs are modelled in the laboratory and
tested in animals. It is naive, however, to
expect only predictable “hard” pharmaco-
logical outcomes. They become an ingredi-
ent in a complex reactive system. This means
it is also naive to believe that the real effect is
that part left over after subtracting the
placebo: one plus one might come out as
four, and you might be one of the active
ingredients.
Creative consulting: more about placebos?
In the fifth article in his series David Reilly is joined by Zelda Di Blasi to look at the placebo response
Universal cultural features in
healing rituals24
 The healer must have a coherent
frame of reference or explanation for
the origin and nature of the problem
and how it can be helped—germs,
curse, chi, etc
 A symbolic bridge is made, integrating
the relationships and situation in
terms of the culture and the healer’s
frame of reference
 The healer aims to activate the bridge
(often subliminally) by persuading the
client that the problem is explainable
in the healer’s frame of reference: “I
can see you have cancer, curses, sup-
pressed anger, irritable bowel, etc”
 Once cognitive consensus is achieved,
emotional involvement is needed
through attachment to the symbols
and frame of reference. Clients have
to be convinced they are possessed by
a spirit, have depression, have food
allergies, etc, and it will kill or damage
them if not treated
 Techniques and guided symbols of
reference are used—for example, pre-
scription, exercise, diet, or exorcism.
Now over time the patient can
reframe the situation in the light of
the healer’s reference—for example, by
talking about the medicine’s effect or
balancing the chakras
 The healed client has a new narrative
and way of functioning. A story is nec-
essary to explain what happened—the
tablets worked, the spirit is gone, etc
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From which carer?
Push the square peg of medicine into the
round hole of healing and you end up with
ugly words, like iatroplacebogenics, to
explain that results are influenced by who
does the caring and how.19 The carer’s per-
sonality and attitude, their warmth, empathy
or hostility towards the patient, and their
attitude towards the treatment (active enthu-
siastic or passive nihilistic) all affect out-
come. A review of controlled trials found
that doctors who adopted a warm, friendly,
and reassuring manner were more effective
than those whose consultations were formal
and did not offer reassurance.20 Good caring
and a weak medicine can give a better out-
come than poor caring and a strong medi-
cine.21 This means that the placebo arm of
one study can sometimes have better results
than the “active” arm of another. This causes
endless confusion and complicates the
search for evidence based practice.
Single blinded design is even less reliable,
which brings us back to expectations. In a
study of people having teeth removed,
patients were told that they might get one of
three injections for pain control that would
make their pain better (fentanyl, a strong
pain killer), worse (naloxone, an opiate
antagonist that would make pain worse), or
have no effect (placebo). The patient was
“blind” but the dentist knew which group
each patient was in.22
The graph shows the response to placebo
in the two groups. When the dentists knew
the patient had a chance of a “real”
painkiller, the placebo was “activated” and
was as distinct from the other placebo
response as a “real” medicine from a dummy
medicine. The carer knew there was a
chance of receiving a “real” medicine and
somehow transmitted this to patients, who
then activated their own healing systems.
We can just as readily destroy such a reac-
tion. Patients receiving eight weeks of
placebo or antidepressants were improving
equally until those taking placebo were told
so.5 Most deteriorated and ended up taking
medications.23
Conclusion
So the treatment, its presentation, and its
expected effects interact with patient factors
blended with the carer and the context to
affect healing systems. It seems that the best
results are achieved when a patient has confi-
dence in the carer, the institution, or the sys-
tem of care, and when these are congruent
with the patient’s attitudes, beliefs, and expec-
tations. Western medicine has often ignored
or marginalised direct engagement with self
healing (hypnotherapy is an important excep-
tion), but, as the box shows, anthropologists
have seen that every human culture expresses
these same dimensions, consciously or not.
David Reilly consultant physician, Homeopathic Hospital,
Glasgow 
davidreilly1@compuserve.com
David Reilly welcomes correspondence or ques-
tions on this series.
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Response of patients when dentists knew
they would get an injection with no chance
of pain relief (PN, placebo or naloxone) or
a 1 in 3 chance of pain relief (PNF,
placebo, naloxone, or fentanyl 22)
(reprinted with permission from Elsevier
Science (The Lancet 1985; i: 43))
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Case history
This 72 year old retired engineer, a for-
mer smoker, presented to his GP com-
plaining of a recent onset cough,
productive of sputum and containing
“spots” of fresh blood. He also said that he
had recently been more breathless than
normal on walking to collect his morning
newspaper.
On examination the left apex was dull to
percussion and there were increased breath
sounds over this area. There was also a
reduction in chest expansion on the left side.
His left eyelid was slightly droopy and the
pupil seemed smaller on that side.
Questions
(1) What preliminary investigations would
you request given the above clinical 
features?
The posteroanterior (PA) and lateral chest
radiographs requested are shown below.
(2) What abnormalities are apparent on
these films?
(3) What further imaging investigations
may be required in the management of this
condition?
(4) What are the main histological types of
this condition?
(5) What is your diagnosis and what are
the characteristic features of the associated
syndrome?
Answers
(1) The following first line investigations
would be necessary given the symptoms in
a former smoker in his 70s: a posteroante-
rior (PA) chest radiograph, sputum cytol-
ogy, full blood count, urea and electrolytes,
liver function tests. A lateral radiograph can
help in localising a lesion within the lung.
(2) The PA chest radiograph shows a
large, poorly defined radio-opaque area in
the right upper lobe of the lung extending
into the apex. This is further shown on the
lateral radiograph.
Sternal wiring indicates a previous
median sternotomy, with surgical clips pro-
jected over the heart consistent with a left
internal mammary artery (LIMA) to left
anterior descending (LAD) coronary graft.
Such a medical history may be related to his
smoking history.
(3) Thoracic computed tomography (CT)
is appropriate to assess and stage the full
extent of the lesion. This may precede or fol-
low bronchoscopy with biopsies/brushings.
CT imaging of the liver and adrenals is rou-
tinely undertaken in the patient with carci-
noma of the lung to exclude intra-abdominal
metastases.
Thoracic CT can also be useful in con-
firming that the lesion’s features are consis-
tent with bronchial malignancy. If alkaline
phosphatase (from the above biochemical
tests) is markedly raised or if “bony” pain is a
further patient complaint a radioisotope
bone scan should be considered to identify
any metastatic bone disease. Clearly, this
would further influence management.
(4) Bronchial carcinomas are typically
divided into small cell lung cancers and
non-small cell lung cancers because the his-
tology determines the management and
prognosis. Non-small cell lung cancers are
further divided into large cell carcinoma,
adenocarcinoma, and squamous cell carci-
noma. Squamous cell carcinoma is the
commonest bronchial carcinoma overall
and is the one most associated with Pan-
coast’s tumour.
(5) The diagnosis is an apical bronchial
carcinoma, specifically a Pancoast’s tumour.
This is an apical bronchial carcinoma associ-
ated with ipsilateral Horner’s syndrome. This
is characterised by ptosis, miosis, enophthal-
mos, and ipsilateral anhydrosis. This is due
to the invasion of the cervical sympathetic
plexus by the encroaching tumour.
Ian C Bickle, final year medical student, Queen’s
University, Belfast 
medicine@totalise.co.uk, 
Barry Kelly consultant radiologist, Royal Victoria
Hospital, Belfast 
Further reading
Dicks E. Chest x rays made easy. studentBMJ
2001;9:10-2.(February 2001.) 
Henry Khumrath Pancoast, 1875-1939, profes-
sor of radiology, University of Pennsylvania,
Philadelphia.
Johann Horner, 1831-83, professor of ophthal-
mology, Zurich. He first described his syndrome
in 1869.
Pancoast’s apical bronchial carcinoma
Key terms
 Miosis—constriction of the pupil
 Enophthalmos—shrunken eye
 Anhydrosis—loss of sweating
Lateral chest radiograph
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If there is an easy way of doing a difficult
task we will take it every time. So it is easy to
see why the experiments carried out by
Rauscher and colleagues in the University
of California in 1993 caused such a stir in
the popular press.1 They suggested that
something as simple as listening to a
Mozart piano sonata might improve your
aptitude for complex tasks.
The authors based their claims on a
series of experiments with 36 college stu-
dents in which volunteers were subjected to
10 minutes of one of three conditions:
silence, a relaxation tape designed to lower
blood pressure, or a recording of Mozart’s
Sonata in D Major for Two Pianos,
K448. After this period, participants’
spatial reasoning skills were tested
using a set of tasks which included pat-
tern analysis and paper folding and cut-
ting. When their performance was
translated into IQ scores, the group
which listened to Mozart displayed a
mean nine point lead over the other two
groups.
Why was Mozart chosen?
The original theory behind the “Mozart
effect” experiments was derived from a
mathematical model of the cerebral cortex.2
The same research group also subjected
music of various types to mathematical
analysis and proposed that certain features
of Mozart’s music meant that it would res-
onate with certain brain regions, notably
those cortical areas involved with spatial
reasoning, “priming” them so that they
would be quicker and more efficient on
future use. This idea of “use dependence” is
a popular one in neuroscience, and the cel-
lular mechanisms involved are a hot topic
in current research.
Controversy and misconception
The original results caused great excite-
ment, generating wild ideas about the mind
expanding powers of the composer. This
was bound to lead to disappointment when
the hypotheses were subjected to more
stringent testing. Rauscher and colleagues
never claimed that Mozart could enhance
all aspects of brain function. Perhaps it was
misleading to translate their subjects’ scores
on the spatial reasoning tasks into IQ rat-
ings, but the authors did not suggest an
effect on general intelligence. Even now,
however, debate continues about the
authenticity of the original results.3
Criticism has been directed at the small
scale of the original study and the suitability
of the controls used, and attempts to repli-
cate the original findings have yielded vary-
ing degrees of success, depending on the
test paradigms used.4
Other groups have suggested that enjoy-
ment of the music and resultant arousal
could explain the improvements seen,3
although 
studies designed specifically to examine the
influence of musical preference have not
supported this.4 More recently, rats exposed
to Mozart in the uterus have shown
improved aptitude for navigation around a
t-maze.5 This is further evidence for an
enhancement of spatial reasoning in the
absence of conscious musical appreciation.
Mozart as medicine
More recently, electroencephalography
(EEG) in patients with epilepsy and those
who were unconscious has shown changes
in brain activity in response to Mozart. This
argues against the enjoyment arousal
theory, at the same time as suggesting inter-
esting and novel avenues for treatment.
EEG measurements taken while patients
were having seizures have shown as much
as a 41% reduction in epileptiform events
while Mozart’s K448 was being played, with
a significant beneficial effect being retained
after the music stopped.6
Similar results were found in both con-
scious and unconscious patients, arguing
against simple relaxation or enjoyment. 
One possible explanation is that features
of Mozart’s music induce patterns of neu-
ronal activity which somehow disrupt those
necessary for the seizure to proceed, “reset-
ting” the brain’s electrical activity. Certainly,
various reports have been made of epileptic
seizures being triggered by certain pieces of
music.7
It is not implausible that other pieces
could have a beneficial effect. Anecdotal
evidence suggests that Mozart might be of
benefit in other neurological conditions,
notably Alzheimer’s disease, stroke, and
Williams syndrome.8
The general consensus
Opinion is still divided on the evidence for
the “Mozart effect,” both in itself and as a
potential neurological treatment. Its origi-
nal proponents defend it vociferously,
and are in the process of developing a
mathematics teaching programme for
primary school children, based on their
neural model. Longer term studies with
children have yielded encouraging
results in terms of subsequent successes
in maths after musical training,9 but the
precise explanation remains cloudy. Music
seems to enhance self esteem and motiva-
tion to attend school, which could account
for a proportion of the effect: thus the
debate rages on.
So Mozart might not be able to turn us
into a mathematical or any other type of
genius, he might not be able to cure neuro-
logical diseases, but it certainly cannot do
any harm. 
My radio is now tuned to Classic FM and
will certainly stay that way in the run up to
exams. It’s worth a try.
Marion Simpson third year medical student, University of
Edinburgh Medical School 
9810930@sms.ed.ac.uk, 
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Will listening to Mozart 
make you smarter?
Marion Simpson investigates an unusual exam aid
